Peripheral Arterial Disease – Landscape And Forecast – Disease Landscape & Forecast
Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis affecting the arteries in the lower extremities. This condition is considered a major marker for systemic ischemic events such as stroke and myocardial infarction. Given that asymptomatic patients make up a large percentage of the total PAD population, it is largely underdiagnosed, under-recognized, and undertreated. However, there is growing recognition that optimal management of PAD requires aggressive secondary prevention measures. PAD treatment is dominated by well-established generic drugs, restricting the overall market value, but emerging therapies, such as stem cell therapies, could significantly boost the market. Overall, the increasing number of prevalent cases, combined with substantial unmet needs and the development of novel therapies, makes the treatment of PAD a high-growth opportunity.
QUESTIONS ANSWERED
- There is a substantial treatment gap in PAD; a considerable percentage of patients remaining undiagnosed and untreated. How do thought leaders believe this treatment gap can be reduced?
- What are the key pharmacotherapeutic agents used for PAD? What are the major unmet needs, according to thought leaders?
- How active is research and development for PAD? What are thought leaders' opinions of the novel therapies in development?
- How will the PAD market grow with the emergence of new branded therapies, and how will these agents impact treatment practice?
CONTENT HIGHLIGHTS
- Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
- Primary research: 17 country-specific interviews with thought-leading PAD experts. Supported by survey data collected for this and other Clarivate research.
- Epidemiology: Prevalence of PAD by country, segmented by disease severity and diagnosed and drug-treated populations.
- Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
- Market forecast features: Ten-year, annualized, drug-level sales and patient share of key PAD therapies through 2029, segmented by brands / generics and epidemiological subpopulations
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Table of contents
- Peripheral Arterial Disease - Landscape And Forecast - Disease Landscape & Forecast
- Key Updates
- Q4 2021
- November 2021
- Q3 2021
- September 2021
- August 2021
- July 2021
- Q2 2021
- June 2021
- May 2021
- April 2021
- Q1 2021
- March 2021
- February 2021
- January 2021
- Q4 2021
- Key Findings
- Peripheral Arterial Disease Key Findings: December 2021
- March 2021
- February 2021
- January 2021
- Peripheral Arterial Disease Key Findings: December 2021
- Market Outlook
- Key Findings
- Market Share of Peripheral Arterial Disease Drug Classes: 2020
- Market Share of Peripheral Arterial Disease Drug Classes: 2030
- Peripheral Arterial Disease SWOT Analysis
- Market Drivers and Constraints
- What Factors Are Driving the Market for Peripheral Arterial Disease?
- What Factors Are Constraining the Market for Peripheral Arterial Disease?
- Sales of Peripheral Arterial Disease Therapies in the Major Pharmaceutical Markets: 2020-2030
- Patient Share of Peripheral Arterial Disease Therapies in the Major Pharmaceutical Markets: 2020-2030
- Drug-Class-Specific Trends
- Major-Market Patient Share of Antiplatelet Agents in Peripheral Arterial Disease: 2020-2030
- Major-Market Sales of Antiplatelet Agents in Peripheral Arterial Disease: 2020-2030
- Major-Market Patient Share of Anticoagulant Agents in Peripheral Arterial Disease: 2020-2030
- Major-Market Sales of Anticoagulant Agents in Peripheral Arterial Disease: 2020-2030
- Patient Share and Sales of Rivaroxaban in Europe: 2020-2030
- Patient Share and Sales of Rivaroxaban in the United States: 2020-2030
- Major-Market Patient Share of Branded Lipid-Lowering Agents in Peripheral Arterial Disease: 2020-2030
- Major-Market Sales of Branded Lipid-Lowering Agents in Peripheral Arterial Disease: 2020-2030
- Patient Share and Sales of REX-001 in Europe: 2020-2030
- Patient Share and Sales of Collategene in Japan: 2020-2030
- Key Findings
- Forecast
- Market Forecast Assumptions - Peripheral Arterial Disease (2020-2030) - November 2021
- Market Forecast Dashboard - Peripheral Arterial Disease (2020-2030) - November 2021
- Etiology and Pathophysiology
- Disease Overview
- Etiology
- Formation of Atherosclerotic Plaque
- Risk Factors for Peripheral Arterial Disease
- Pathophysiology
- The Response-to-Injury Hypothesis of Atherosclerosis
- Atherosclerotic Plaque Architecture
- American Heart Associationu2019s Atherosclerotic Lesion Classifications
- Atherosclerotic Plaque Rupture
- Features and Consequences of Plaque Erosion
- Thrombus Formation
- Disease Stages of Peripheral Arterial Disease
- Comparison of the Classification Systems for Peripheral Arterial Disease
- Key Pathways and Drug Targets
- Peripheral Arterial Disease Drug Targets
- Disease Overview
- Epidemiology
- Key Findings
- Epidemiology Populations
- Total Prevalent Cases of Peripheral Arterial Disease: 2020-2030 (Thousands)
- Total Prevalent Cases of Peripheral Arterial Disease by Severity: 2020-2030 (Thousands)
- Diagnosed Prevalent Cases of Peripheral Arterial Disease: 2020-2030
- Drug-Treated Prevalent Cases of Peripheral Arterial Disease: 2020-2030
- Key Findings
- Current Treatment
- Key Findings
- Treatment Goals
- Key Endpoints Used in Clinical Trials for Peripheral Arterial Disease
- Key Current Therapies
- Overview
- Mechanism of Action of Key Current Drug Classes Used for Peripheral Arterial Disease
- Current Treatments Used for Peripheral Arterial Disease
- Market Events Impacting the Use of Key Current Therapies for Peripheral Arterial Disease
- Advantages and Disadvantages of Aspirin
- Advantages and Disadvantages of Clopidogrel
- Advantages and Disadvantages of Sarpogrelate
- Expert Insight: Antiplatelet Agents
- Advantages and Disadvantages of Vorapaxar
- Key Results From Select Clinical Trials Investigating Vorapaxar for the Treatment of Peripheral Arterial Disease
- Advantages and Disadvantages of Vitamin K Antagonists
- Advantages and Disadvantages of Rivaroxaban
- Key Results From Select Clinical Trials Investigating Rivaroxaban for the Treatment of Peripheral Arterial Disease
- Ongoing Clinical Development of Rivaroxaban
- Expert Insight: Anticoagulant Agents
- Advantages and Disadvantages of Statins
- Expert Insight: Statins
- Advantages and Disadvantages of Cholesterol Absorption Inhibitors
- Advantages and Disadvantages of Evolocumab
- Key Results From Select Clinical Trials Investigating Evolocumab for the Treatment of Peripheral Arterial Disease
- Advantages and Disadvantages of Alirocumab
- Key Results From Select Clinical Trials Investigating Alirocumab
- Ongoing Clinical Development of Alirocumab
- Expert Insight: PCSK9 Inhibitors
- Advantages and Disadvantages of Vascepa
- Key Results From Select Clinical Trials Investigating Vascepa for the Treatment of Dyslipidemia
- Key Results From Select Clinical Trials Investigating Nexletol / Nexlizet for the Treatment of Dyslipidemia
- Analysis of Clinical Development Program for Nexletol / Nexlizet
- Expert Insight: Nexletol / Nexlizet
- Advantages and Disadvantages of ACE Inhibitors and ARBs
- Expert Insight: ACE Inhibitors and ARBs
- Advantages and Disadvantages of Beta Blockers
- Expert Insight: Beta Blockers
- Advantages and Disadvantages of Calcium Channel Blockers
- Expert Insight: Calcium Channel Blockers
- Advantages and Disadvantages of Cilostazol
- Advantages and Disadvantages of Pentoxifylline
- Advantages and Disadvantages of Naftidrofuryl
- Expert Insight: Vasoactive Agents
- Advantages and Disadvantages of Prostaglandin Analogues
- Expert Insight: Prostaglandin Analogues
- Advantages and Disadvantages of Beperminogene Perplasmid
- Key Results From Selected Clinical Trials Investigating Beperminogene Perplasmid
- Key Ongoing Clinical Trials of Beperminogene Perplasmid
- Exercise Therapy
- Revascularization and Surgical Procedures
- Medical Practice
- Overview
- Factors Influencing Drug Selection in Peripheral Arterial Disease
- Treatment Decision Tree for Peripheral Arterial Disease: United States
- Treatment Decision Tree for Peripheral Arterial Disease: Europe
- Treatment Decision Tree for Peripheral Arterial Disease: Japan
- Key Findings
- Unmet Need Overview
- Current and Future Attainment of Unmet Needs in Peripheral Arterial Disease
- Top Unmet Needs in Peripheral Arterial Disease: Current and Future Attainment
- Expert Insight: Unmet Need in Peripheral Arterial Disease
- Emerging Therapies
- Key Findings
- Key Emerging Therapies
- Key Therapies in Development for Peripheral Arterial Disease
- Estimated Launch Dates of Key Emerging Therapies for the Treatment of Peripheral Arterial Disease
- Analysis of Clinical Developmental Program for Rexmyelocel-T (REX-001)
- Expectations for Launch and Sales Opportunity of Rexmyelocel-T (REX-001) in Peripheral Arterial Disease
- Honedra (CLBS12)
- Honedra (CLBS-12) Profile
- Expectations for Launch and Sales Opportunity of Honedra in Peripheral Arterial Disease
- Expert Insight: Stem Cell Therapies
- Inclisiran Profile
- Analysis of Clinical Development Program for Inclisiran
- Expert Insight: Inclisiran
- Expectations for Launch and Sales Opportunity of Inclisiran in Peripheral Arterial Disease
- Semaglutide Profile
- Expectations for Launch and Sales Opportunity of Semaglutide in Peripheral Arterial Disease
- Early-Phase Pipeline Analysis
- Select Compounds in Early-Phase Development for Peripheral Arterial Disease
- Key Discontinuations and Failures
- Key Findings
- Access & Reimbursement Overview
- Region-Specific Reimbursement Practices
- Key Market Access Considerations in Peripheral Arterial Disease: United States
- General Reimbursement Environment: United States
- Key Market Access Considerations in Peripheral Arterial Disease: EU5
- General Reimbursement Environment: EU5
- Key Market Access Considerations in Peripheral Arterial Disease: Japan
- General Reimbursement Environment: Japan
- Region-Specific Reimbursement Practices
- Appendix
- Peripheral Arterial Disease Bibliography
- Key Updates
Shambhavi Shukla, MTech., is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. Before joining Clarivate, Shambhavi was with Evalueserve for four years, where she worked closely with top pharmaceutical companies, helping them with commercial and technical ad-hoc requests. She has delivered competitive landscape and market insight projects for various indications, including Schizophrenia, Multiple Sclerosis, Myopia, Osteoporosis, and FSGS. She holds a master’s degree in biotechnology from Amity University, India.